|Bid||65.00 x 1200|
|Ask||69.99 x 1100|
|Day's Range||65.52 - 67.08|
|52 Week Range||45.31 - 69.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Seattle Genetics, Inc. (SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target Tissue Factor antigen on cancer cell surfaces and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells. The Tissue Factor antigen target is overexpressed in the vast majority of patients with cervical cancer and in many other solid tumors, including ovarian, lung, pancreatic, colorectal and head and neck.
On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
Seattle Genetics, Inc. announced today that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m.
Seattle Genetics, Inc. today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma at the 2018 American Society of Clinical Oncology Annual Meeting being held June 1-5 in Chicago, Illinois.
Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. In this phase 1 study (EV-101), enfortumab vedotin was evaluated as monotherapy for patients with metastatic urothelial cancer including patients who previously received a checkpoint inhibitor. This phase 1 study is part of a broader program focused on investigating enfortumab vedotin in both monotherapy and in combination with a checkpoint inhibitor for locally advanced or metastatic urothelial cancer.
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- TOKYO and BOTHELL, Wash. , June 3, 2018 /PRNewswire/ -- ...
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union. ...
Seattle Genetics, Inc. (SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. “Roger’s appointment reflects the growing importance of late-stage clinical drug development at Seattle Genetics as we transition to a global, multi-product oncology company,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics.
Seattle Genetics, Inc. today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, from June 1-5, 2018.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson ...
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences.
Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m.
Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2018. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, and progress with its late-stage clinical programs and pipeline of targeted therapies for cancer.
Seattle Genetics, Inc. today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate platform technologies as well as its emerging immuno-oncology pipeline.
Seattle Genetics, Inc. announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate , for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors .
Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has approved ADCETRIS in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Seattle Genetics, Inc. announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen.
Seattle Genetics, Inc. announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time.
Seattle Genetics, Inc. today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced program in Cascadian Therapeutics’ pipeline is tucatinib, an investigational oral tyrosine kinase inhibitor that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric....
Seattle Genetics, Inc. today announced the expiration of the tender offer by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
Seattle Genetics, Inc. today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma .
Seattle Genetics, Inc. announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m.